Cryosite Limited
AU:
CTE
-
AUD
DIAGNOSTICS & RESEARCH
A$0.43
+A$0.01
(+2.38%)
How to buy Cryosite (CTE) shares
Learn how to easily invest in Cryosite shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cryosite Limited is a diagnostics & research business based in Australia. Cryosite shares (CTE) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Cryosite has a trailing 12-month revenue of around $9.7 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Cryosite
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Cryosite . Find the share by name or ticker symbol: CTE. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cryosite reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Cryosite . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Our top pick for
US stocks
Finder Award
Our top pick for
Cheap broker fees
Finder Award
Our top pick for
Long-term investing
Finder Award
What's in this guide?
Cryosite stock price (ASX:CTE)
Use our graph to track the performance of CTE stocks over time.Cryosite shares at a glance
Information last updated 2021-07-22.
| 52-week range | $0.14 - $0.46 |
|---|---|
| 50-day moving average | $0.3988 |
| 200-day moving average | $0.3339 |
| Target price | N/A |
| PE ratio | 38.1818 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.011 |
Compare share trading platforms
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy Cryosite stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Cryosite price performance over time
Historical closes compared with the last close of A$0.36
| 1 month (2021-06-29) | -10.00% |
|---|---|
| 3 months (2021-04-29) | 38.46% |
Is Cryosite under- or over-valued?
Valuing Cryosite stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cryosite 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cryosite 's P/E ratio
Cryosite 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, Cryosite shares trade at around 38x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cryosite 's EBITDA
Cryosite 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $887,656.
The EBITDA is a measure of a Cryosite 's overall financial performance and is widely used to measure a its profitability.
Cryosite financials
| Revenue TTM | $9.7 million |
|---|---|
| Operating margin TTM | 8.08% |
| Gross profit TTM | $4 million |
| Return on assets TTM | 2.08% |
| Return on equity TTM | 0% |
| Profit margin | 5.35% |
| Book value | -0.037 |
| Market capitalisation | $19.7 million |
TTM: trailing 12 months
Cryosite share dividends
We're not expecting Cryosite to pay a dividend over the next 12 months.
Have Cryosite 's shares ever split?
Cryosite 's shares were split on 28 April 2004.
Cryosite share price volatility
Over the last 12 months, Cryosite 's shares have ranged in value from as little as $0.14 up to $0.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cryosite 's is 0.3501. This would suggest that Cryosite 's shares are less volatile than average (for this exchange).
Cryosite overview
Cryosite Limited engages in the supply chain logistics and management of pharmaceutical products used in clinical trials, and biological materials in Australia. It operates in two segments, Clinical Trials & Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials & Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, and biological storage services to the clinical trial and research industry. The Cord Blood and Tissues Storage segment offers long term storage for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. Cryosite Limited was founded in 1999 and is based in South Granville, Australia.
Stocks similar to Cryosite
Cryosite in the news
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
-
How to invest in the X2M Connect IPO
Everything we know about the X2M Connect IPO, plus information on how to buy in.
-
How to buy Industrial Minerals (IND.AU) shares
Steps to owning and managing Industrial Minerals shares.
-
How to invest in the SSH Group IPO
Everything we know about the SSH Group IPO, plus information on how to buy in.
-
Why is the CSL share price bouncing back?
Shares in biotech giant CSL are up 6% in the past year and have seen a bounceback over the last few sessions.
-
How to invest in the Iris Metals IPO
Everything we know about the Iris Metals IPO, plus information on how to buy in.
-
Why is the Crown Resorts (CWN) share price sinking?
Shares in the casino operator have lost a quarter of their value from a year-high hit in May.
-
How to invest in the Li-S Energy IPO
Everything we know about the Li-S Energy IPO, plus information on how to buy in.
-
How to invest in the Clarity Pharmaceuticals IPO IPO
Everything we know about the Clarity Pharmaceuticals IPO IPO, plus information on how to buy in.
-
How to invest in the TEK-Ocean Group IPO
Everything we know about the TEK-Ocean Group IPO, plus information on how to buy in.
-
How to buy HNC Coin (HNC) in Australia
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
Ask an Expert
